HomePRESS RELEASESCanopus BioPharma Strengthens Its CB1400 Platform Technology for Mucositis and Oncology Treatments...
Canopus BioPharma Strengthens Its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement with Wisconsin Alumni Research Foundation